2023 / 03

Next Paper
DOI: 10.47183/mes.2023.024

ORIGINAL RESEARCH

Polymorphism of interleukin control genes and risk of neoplasms in exposed individuals

Blinova EA1,2, Yanishevskaya MA1, Akleyev AV1,2
About authors

1 Ural Research Center for Radiation Medicine, Chelyabinsk, Russia

2 Chelyabinsk State University, Chelyabinsk, Russia

Correspondence should be addressed: Eugenia A. Blinova
Vorovskogo st., 68, bldg. A, Chelyabinsk, 454141, Russia; ur.mrcru@avonilb

About paper

Funding: the study received funding in the context of the Federal Target Program "Ensuring nuclear and radiation safety in 2016-2020 and up to 2030" (State Contract #11.313.21.2 of June 15, 2021).

Author contribution: EA Blinova — generalization of primary material, analysis and discussion of results, article text authoring; MA Yanishevskaya — statistical processing of primary data; AV Akleyev — study planning, article editing.

Compliance with the ethical standards: the study was approved by the Ethics Committee of the Urals Research Center for Radiation Medicine of the FMBA of Russia (Minutes #4 of June 8, 2023). All procedures on humans performed in the context of the study conform to the requirements of the 1964 Helsinki Declaration and its subsequent amendments or comparable ethical standards. Each participant of the study signed the voluntary informed consent form.

Received: 2023-06-09 Accepted: 2023-07-20 Published online: 2023-08-12
|
  1. Teletaeva GM. Citokiny i protivoopuxolevyj immunitet. Prakticheskaya onkologiya. 2007; 8 (4): 211–18. Russian.
  2. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32 (19–20): 1267–84.
  3. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumourassociated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14 (7): 399–416.
  4. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tum our Biol. 2016; 37 (9): 11553–72.
  5. Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, et al. IL8, Neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. Clin Cancer Res. 2021; 27 (9): 2383v93.
  6. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021; 21 (8): 481–99.
  7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144: 646–74.
  8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860–7.
  9. Lumniczky K, Impens N, Armengol G, Candeias S, Georgakilas AG, Hornhardt S, et al. Low dose ionizing radiation effects on the immune system. Environment International. 2021; 149: 106212.
  10. I. Shigematsu C. Kamada Ito N. Effects of A-bomb radiation on the human body. Tokyo: Harwood academic publishers. Bunkodo Co., 1995; 419 s.
  11. Hayashi T, Kusunoki Y, Hakoda M, Morishita Y, Kubo Y, Maki M, et al. Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors. International Journal of Radiation Biology. 2003; 79 (2): 129–36.
  12. Hayashi T, Morishita Y, Kubo Y, Kusunoki Y, Hayashi I, Kasagi F, et al. Long-term effects of radiation dose on inflammatory markers in atomic bomb survivors. The American Journal of Medicine. 2005; 118 (1): 83–86.
  13. Senyuk OF, Kavsan VM, Müller WE, Schröder HC. Long-term effects of low-dose irradiation on human health. Cellular and Molecular Biology. 2002; 48 (4): 393–409.
  14. Akleev AA. Immunnyj status cheloveka v otdalennom periode xronicheskogo radiacionnogo vozdejstviya. Medicinskaya radiologiya i radiacionnaya bezopasnost'. 2020; 65 (4): 29–35. Russian.
  15. Kodinceva EA, Akleev AA, Blinova EA. Citokinovyj profil' lic, podvergshixsya xronicheskomu radiacionnomu vozdejstviyu, v otdalennye sroki posle oblucheniya. Radiacionnaya biologiya. Radioehkologiya. 2021; 61 (5): 506–14. Russian.
  16. Gordeeva LA, Mun SA, Voronina EN, Polenok EG, Magatina AD, Titov VA, i dr. Associacii polimorfizma v genax citokinov s riskom ploskokletochnogo raka legkogo u muzhchin v zavisimosti ot dlitel'nosti kureniya. Ehkologicheskaya genetika. 2018; 16 (1): 60–69. Russian.
  17. Shen Y, Liu Y, Liu S, Zhang A. The association between –330T/G polymorphism of interleukin 2 gene and bladder cancer. DNA and Cell Biology. 2012; 31: 983–7.
  18. Wei YS, Lan Y, Zhang L, Wang JC. Association of the interleukin-2 polymorphisms with interleukin-2 serum levels and risk of nasopharyngeal carcinoma. DNA and cell biology. 2010; 29 (7): 363–8.
  19. Song H, Chen L, Cha Z, Bai J. Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol. 2012; 31 (7): 1279–84.
  20. Jia Y, Xie X, Shi X, Li S. Associations of common IL4 gene polymorphisms with cancer risk: A meta-analysis. Mol Med Rep. 2017; 16 (2): 1927–45.
  21. Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, et al. Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget. 2018; 9 (15): 12351–64.
  22. Moghimi M, Alireza Dastgheib S, Heiranizadeh N, Zare M, Sheikhpour E, H. Neamatzadeh H. Association of IL-8 ‒251T>A (rs4073) polymorphism with susceptibility to gastric cancer: a systematic review and meta-analysis based on 33 case-control studies. Gastroenterol. 2020; 57 (01): 91–99.
  23. Akleev AV, Kiselev MF, redaktory. Mediko-biologicheskie i ehkologicheskie posledstviya radioaktivnogo zagryazneniya reki Techa. M.: Vtoraya tipografiya FU «Medbioehkstrem», 2001; 531 s. Russian.
  24. Degteva MO, Nape BA, Tolstyx EI, Shishkina EA, Bugrov NG, Krestinina LYu, i dr. Raspredelenie individual'nyx doz v kogorte lyudej, obluchennyx v rezul'tate radioaktivnogo zagryazneniya reki Techi. Medicinskaya radiologiya i radiacionnaya bezopasnost'. 2019; 64 (3): 46–53. Russian.
  25. Bland JM. Statistics Notes: The odds ratio. BMJ. 2000; 320 (7247): 1468.
  26. Akleev AA, Blinova EA, Akleev AV. Odnonukleotidnye polimorfizmy kak biomarkery otdalennyx radiacionno-inducirovannyx izmenenij sistemnogo immuniteta. Patogenez. 2021; 19 (3): 38–49. Russian.
  27. Jain J, Valge-Archer VE, Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J Immunol. 1992; 148 (4): 1240–50.
  28. Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5’-untranslated regions of eukaryotic mRNAs. Science. 2016; 352 (6292): 1413–6.
  29. Robert F, Pelletier J. Exploring the impact of single-nucleotide polymorphisms on translation. Front Genet. 2018; 9: 507.
  30. Mueller WF, Larsen LS, Garibaldi A, Hatfield GW, Hertel KJ. The Silent Sway of Splicing by Synonymous Substitutions. The Journal of biological chemistry. 2015; 290 (46): 27700–11.